Gosuranemab

戈奈单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGosuranemab
Drug Alias NameAnti-tau-mAbAnti-eTauBMS-986168IPN-007BIIB-092 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsMacular DegenerationTauopathiesFrontotemporal Dementia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIpierian IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoBiogen Inc
Active IndicationsN/A
Inactive IndicationsMacular DegenerationTauopathiesFrontotemporal Dementia +[5] 

Other Information

ATC CodeN/A
Related LinksN/A